Trial · NCT00781937
Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance
NCT00781937, Phase 3, Completed, Novo Nordisk A/S; results first posted 2011-11-28
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance. Trials, record NCT00781937. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00781937
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance
- NCT number
- NCT00781937
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 422 participants, actual
- Lead sponsor
- Novo Nordisk A/S
- Conditions
- Metabolism and Nutrition Disorder, Obesity
- Interventions
- liraglutide, placebo
- First posted
- 2008-10-29
- Last updated
- 2017-11-01
- Results first posted
- 2011-11-28
Source ClinicalTrials.gov
Registered outcomes26
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean Percentage Change in Fasting Body Weight From Baseline | Week 0, week 56 | Subjects were weighed having fasted (consumed only water) since midnight the night before the visit. |
| Primary | Percentage of Subjects Who Maintained Their run-in Fasting Weight Loss From Week 0 | Week 0, week 56 | Subjects who had a weight regain less than or equal to 0.5% of weight from Week 0 were regarded as maintenance of run-in fasting weight loss. Subjects were weighed having fasted (consumed only water) since midnight the night before the visit. |
| Primary | Percentage of Subjects Who Lost More Than or Equal to 5% of Fasting Body Weight From Week 0 | Week 0, week 56 | Subjects were weighed having fasted (consumed only water) since midnight the night before the visit. |
| Secondary | Percentage of Subjects Who Lost More Than 10% of Fasting Body Weight From Week 0 | Week 0, week 56 | Subjects were weighed having fasted (consumed only water) since midnight the night before the visit. |
| Secondary | Percentage of Subjects With Weight Regain (Fasting) More Than or Equal to 5% From Week 0 | Week 0, week 56 | Subjects were weighed having fasted (consumed only water) since midnight the night before the visit. |
| Secondary | Percentage of Subjects With Weight Regain (Fasting) More Than or Equal to 10% From Week 0 | Week 0, week 56 | Subjects were weighed having fasted (consumed only water) since midnight the night before the visit. |
| Secondary | Percentage of Subjects With Greater Than 50% of Fasting run-in Weight Loss Maintained From Week 0 | Week 0, week 56 | Subjects were weighed having fasted (consumed only water) since midnight the night before the visit. |
| Secondary | Percentage of Subjects With Greater Than 75% of Fasting run-in Weight Loss Maintained From Week 0 | Week 0, week 56 | Subjects were weighed having fasted (consumed only water) since midnight the night before the visit. |
| Secondary | Change From Baseline in Fasting Weight | Week 0, week 56 | Subjects were weighed having fasted (consumed only water) since midnight the night before the visit. |
| Secondary | Change From Baseline in Fasting Weight for Subjects Completing the Main Trial Period and Entering the Follow-up Period | Week 0, week 68 | Subjects were weighed having fasted (consumed only water) since midnight the night before the visit. |
1 to 10 of 26Source ClinicalTrials.gov
See all 26 registered outcomesOutcomes26
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Mean Percentage Change in Fasting Body Weight From Baseline | Week 0, week 56 | Last Observation Carried Forward, Full Analysis Set (includes all randomised subjects exposed to at least 1 dose of trial product and with at least 1 post-randomisation assessment of any efficacy endpoint.) | percentage | LEAST_SQUARES_MEAN |
| PRIMARY | Percentage of Subjects Who Maintained Their run-in Fasting Weight Loss From Week 0 | Week 0, week 56 | Last Observation Carried Forward, Full Analysis Set (includes all randomised subjects exposed to at least 1 dose of trial product and with at least 1 post-randomisation assessment of any efficacy endpoint.) | percentage of subjects | NUMBER |
| PRIMARY | Percentage of Subjects Who Lost More Than or Equal to 5% of Fasting Body Weight From Week 0 | Week 0, week 56 | Last Observation Carried Forward, Full Analysis Set (includes all randomised subjects exposed to at least 1 dose of trial product and with at least 1 post-randomisation assessment of any efficacy endpoint.) | percentage of subjects | NUMBER |
| SECONDARY | Percentage of Subjects Who Lost More Than 10% of Fasting Body Weight From Week 0 | Week 0, week 56 | Full Analysis Set (includes all randomised subjects exposed to at least 1 dose of trial product and with at least 1 post-randomisation assessment of any efficacy endpoint.) | percentage of subjects | NUMBER |
| SECONDARY | Percentage of Subjects With Weight Regain (Fasting) More Than or Equal to 5% From Week 0 | Week 0, week 56 | Full Analysis Set (includes all randomised subjects exposed to at least 1 dose of trial product and with at least 1 post-randomisation assessment of any efficacy endpoint.) | percentage of subjects | NUMBER |
| SECONDARY | Percentage of Subjects With Weight Regain (Fasting) More Than or Equal to 10% From Week 0 | Week 0, week 56 | Full Analysis Set (includes all randomised subjects exposed to at least 1 dose of trial product and with at least 1 post-randomisation assessment of any efficacy endpoint.) | percentage of subjects | NUMBER |
| SECONDARY | Percentage of Subjects With Greater Than 50% of Fasting run-in Weight Loss Maintained From Week 0 | Week 0, week 56 | Full Analysis Set (includes all randomised subjects exposed to at least 1 dose of trial product and with at least 1 post-randomisation assessment of any efficacy endpoint.) | percentage of subjects | NUMBER |
| SECONDARY | Percentage of Subjects With Greater Than 75% of Fasting run-in Weight Loss Maintained From Week 0 | Week 0, week 56 | Full Analysis Set (includes all randomised subjects exposed to at least 1 dose of trial product and with at least 1 post-randomisation assessment of any efficacy endpoint.) | percentage of subjects | NUMBER |
| SECONDARY | Change From Baseline in Fasting Weight | Week 0, week 56 | Last Observation Carried Forward, Full Analysis Set (includes all randomised subjects exposed to at least 1 dose of trial product and with at least 1 post-randomisation assessment of any efficacy endpoint.) | kg | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Fasting Weight for Subjects Completing the Main Trial Period and Entering the Follow-up Period | Week 0, week 68 | Last Observation Carried Forward, Full Analysis Set (includes all randomised subjects exposed to at least 1 dose of trial product and with at least 1 post-randomisation assessment of any efficacy endpoint.) | kg | LEAST_SQUARES_MEAN |
1 to 10 of 26Source ClinicalTrials.gov
See all 26 outcomesResults by group68
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Percentage Change in Fasting Body Weight From Baseline | Lira 3.0 mg | -6.11 | Standard Error 0.66 | percentage | |
| Mean Percentage Change in Fasting Body Weight From Baseline | Placebo | -0.05 | Standard Error 0.63 | percentage | |
| Percentage of Subjects Who Maintained Their run-in Fasting Weight Loss From Week 0 | Lira 3.0 mg | 80.8 | percentage of subjects | ||
| Percentage of Subjects Who Maintained Their run-in Fasting Weight Loss From Week 0 | Placebo | 47.9 | percentage of subjects | ||
| Percentage of Subjects Who Lost More Than or Equal to 5% of Fasting Body Weight From Week 0 | Lira 3.0 mg | 50.5 | percentage of subjects | ||
| Percentage of Subjects Who Lost More Than or Equal to 5% of Fasting Body Weight From Week 0 | Placebo | 21.9 | percentage of subjects | ||
| Percentage of Subjects Who Lost More Than 10% of Fasting Body Weight From Week 0 | Lira 3.0 mg | 26.1 | percentage of subjects | ||
| Percentage of Subjects Who Lost More Than 10% of Fasting Body Weight From Week 0 | Placebo | 6.3 | percentage of subjects | ||
| Percentage of Subjects With Weight Regain (Fasting) More Than or Equal to 5% From Week 0 | Lira 3.0 mg | 1.9 | percentage of subjects | ||
| Percentage of Subjects With Weight Regain (Fasting) More Than or Equal to 5% From Week 0 | Placebo | 17.5 | percentage of subjects |
1 to 10 of 68Source ClinicalTrials.gov
See all 68 results by groupParticipant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Main Trial Period Through Week 56 | STARTED | Lira 3.0 mg | 212 | |
| Main Trial Period Through Week 56 | STARTED | Placebo | 210 | |
| Main Trial Period Through Week 56 | COMPLETED | Lira 3.0 mg | 159 | |
| Main Trial Period Through Week 56 | COMPLETED | Placebo | 146 | |
| Main Trial Period Through Week 56 | NOT COMPLETED | Lira 3.0 mg | 53 | |
| Main Trial Period Through Week 56 | NOT COMPLETED | Placebo | 64 | |
| Follow up Period (Week 56-68) | STARTED | Lira 3.0 mg | 159 | |
| Follow up Period (Week 56-68) | STARTED | Placebo | 146 | |
| Follow up Period (Week 56-68) | COMPLETED | Lira 3.0 mg | 153 | |
| Follow up Period (Week 56-68) | COMPLETED | Placebo | 141 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events78
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nasopharyngitis | Infections and infestations | Lira 3.0 mg | 36 | 212 | 44 |
| other | Nasopharyngitis | Infections and infestations | Placebo | 47 | 210 | 63 |
| other | Sinusitis | Infections and infestations | Lira 3.0 mg | 16 | 212 | 17 |
| other | Sinusitis | Infections and infestations | Placebo | 27 | 210 | 33 |
| other | Upper Respiratory Tract Infection | Infections and infestations | Lira 3.0 mg | 26 | 212 | 35 |
| other | Upper Respiratory Tract Infection | Infections and infestations | Placebo | 23 | 210 | 33 |
| other | Influenza | Infections and infestations | Lira 3.0 mg | 15 | 212 | 17 |
| other | Influenza | Infections and infestations | Placebo | 22 | 210 | 25 |
| other | Urinary Tract Infection | Infections and infestations | Lira 3.0 mg | 15 | 212 | 17 |
| other | Urinary Tract Infection | Infections and infestations | Placebo | 11 | 210 | 11 |
1 to 10 of 78Source ClinicalTrials.gov
See all 78 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Lira 3.0 mg | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Lira 3.0 mg | 177 | 212 |
| Total, other adverse events | Placebo | 163 | 210 |
| Total, serious adverse events | Lira 3.0 mg | 9 | 212 |
| Total, serious adverse events | Placebo | 5 | 210 |
Source ClinicalTrials.gov
Papers7
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Lira 3.0 mg vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00781937
GET https://conductscience.org/api/trials/v1/NCT00781937/registered?page=2